News

Press Releases

Press Releases

Press Releases

August 8, 2019
Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, by end of Q3 2019 BRIDGEWATER, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc